Navigation path

Pharmaceuticals - Union Register


Register of orphan medicinal products


Product information

Pegylated recombinant factor VIII

EU orphan designation number: EU/3/12/995   
Active ingredient: Pegylated recombinant factor VIII
Indication: Treatment of haemophilia A
Sponsor: Novo Nordisk A/S
Novo Allé, 2880 Bagsvaerd, Danmark

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
30/04/2012 Orphan designation EMA/OD/144/11 (2012)2990 of 26/04/2012